1,1-Bis(3′-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease γ-radiation-induced survivin in colon and pancreatic cancer cells

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1191-1199

  Sreevalsan, Sandeep ^a   Jutooru, Indira ^a   Chadalapaka, Gayathri ^a   Walker, Michael ^b   Safe, Stephen ^a,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

radiation induced survivin; DIM analogs; Survivin downregulation

Indexed keywords

1,1 BIS(3' INDOYL) 1 (P BROMOPHENYL)METHANE; 2,2' DIMETHYL 1,1 BIS(3' INDOYL) 1 (P BROMOPHENYL)METHANE; ANTINEOPLASTIC AGENT; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; GAMMA RADIATION; GENE ACTIVATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN FUNCTION; RADIOSENSITIVITY; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GAMMA RAYS; GENE EXPRESSION; HUMANS; INDOLES; MICROTUBULE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 70449579240     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000436     Document Type: Article

References (46)

1. Altieri DC: The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18: 609-615, 2006.
2. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
3. Stauber RH, Mann W and Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67: 5999-6002, 2007. (Pubitemid 47037475)
4. Lens SM, Vader G and Medema RH: The case for Survivin as mitotic regulator. Curr Opin Cell Biol 18: 616-622, 2006.
5. Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139, 2007. (Pubitemid 47062670)
6. Xing Z, Conway EM, Kang C and Winoto A: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 199: 69-80, 2004. (Pubitemid 38076479)
7. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A and Crispino JD: Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA 102: 11480-11485, 2005. (Pubitemid 41153845)
8. Deguchi M, Shiraki K, Inoue H, et al: Expression of survivin during liver regeneration. Biochem Biophys Res Commun 297: 59-64, 2002.
9. Chiou SK, Moon WS, Jones MK and Tarnawski AS: Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem Biophys Res Commun 305: 374-379, 2003.
10. Yang L, Cao Z, Yan H and Wood WC: Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 63: 6815-6824, 2003. (Pubitemid 37322964)
11. Zaffaroni N, Pennati M and Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360-372, 2005.
12. Wu J, Ling X, Pan D, et al: Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 280: 9745-9751, 2005. (Pubitemid 40409673)
13. Li F and Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J 344: 305-311, 1999. (Pubitemid 30011584)
14. Chadalapaka G, Jutooru I, Chintharlapalli S, et al: Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 68: 5345-5354, 2008.
15. Kawakami H, Tomita M, Matsuda T, et al: Transcriptional activation of survivin through the NF-κB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115: 967-974, 2005. (Pubitemid 40791839)
16. Zhu N, Gu L, Findley HW, et al: KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 281: 14711-14718, 2006. (Pubitemid 43855176)
17. Raj D, Liu T, Samadashwily G, Li F and Grossman D: Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29: 194-201, 2008.
18. Hinnis AR, Luckett JC and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96: 639-645, 2007.
19. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI and Shariat SF: Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70: 482-486, 2007. (Pubitemid 47464512)
20. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI and Lotan Y: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109: 1106-1113, 2007. (Pubitemid 46435389)
21. Adida C, Recher C, Raffoux E, et al: Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111: 196-203, 2000. (Pubitemid 30832451)
22. Adida C, Haioun C, Gaulard P, et al: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96: 1921-1925, 2000.
23. Nomura T, Yamasaki M, Nomura Y and Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 14: 993-997, 2005.
24. Zhang M, Latham DE, Delaney MA and Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482, 2005. (Pubitemid 40593038)
25. Zaffaroni N, Pennati M, Colella G, et al: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59: 1406-1412, 2002. (Pubitemid 35041794)
26. Ling X, Bernacki RJ, Brattain MG and Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 279: 15196-15203, 2004. (Pubitemid 38618915)
27. Rodel F, Hoffmann J, Distel L, et al: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65: 4881-4887, 2005. (Pubitemid 40740827)
28. Garcia-Barros M, Paris F, Cordon-Cardo C, et al: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159, 2003. (Pubitemid 36583102)
29. Asanuma K, Moriai R, Yajima T, et al: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91: 1204-1209, 2000.
30. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R and Rodel F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55: 1341-1347, 2003. (Pubitemid 36338302)
31. Chintharlapalli S, Papineni S and Safe S: 1,1-Bis(3′-indolyl)-1-(p- substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways. Mol Cancer Ther 5: 1362-1370, 2006. (Pubitemid 43881330)
32. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S and Kamat AM: Inhibition of bladder tumor growth by 1,1- bis(3′-indolyl)-1-(p- substituted phenyl)methanes: a new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res 66: 412-418, 2006. (Pubitemid 43166049)
33. Vanderlaag K, Su Y, Frankel AE, et al: 1,1-Bis(3′-indolyl)-1-(p- substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res Treat 109: 273-283, 2008. (Pubitemid 351644847)
34. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S and Singh M: Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 15: 543-552, 2009.
35. Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K and Safe S: Activation of Nur77 by selected 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J Biol Chem 280: 24903-24914, 2005. (Pubitemid 40934582)
36. Cho SD, Yoon K, Chintharlapalli S, et al: Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and independent pathways. Cancer Res 67: 674-683, 2007. (Pubitemid 46192207)
37. Lei P, Abdelrahim M, Cho SD, Liu S, Chintharlapalli S and Safe S: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-Jun N-terminal kinase. Carcinogenesis 29: 1139-1147, 2008.
38. Lei P, Abdelrahim M, Cho SD, Liu X and Safe S: Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3′-indoly)-1-(p-substituted phenyl)methanes. Mol Cancer Ther 7: 3363-3372, 2008.
39. Li F, Ling X, Huang H, et al: Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24: 1385-1395, 2005. (Pubitemid 40343118)
40. Lu M, Kwan T, Yu C, et al: Peroxisome proliferator-activated receptor γ agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 280: 6742-6751, 2005. (Pubitemid 40341229)
41. Esteve PO, Chin HG and Pradhan S: Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282: 2615-2625, 2007.
42. Cip1-dependent decrease in survivin levels. Cancer Res 67: 6987-6994, 2007.
43. Kaneko R, Tsuji N, Asanuma K, Tanabe H, Kobayashi D and Watanabe N: Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 282: 19273-19281, 2007. (Pubitemid 47100098)
44. Pyrko P, Soriano N, Kardosh A, et al: Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5: 19, 2006. (Pubitemid 43919219)
45. Ahn KS, Sethi G, Krishnan K and Aggarwal BB: γ-tocotrienol inhibits nuclear factor-κB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem 282: 809-820, 2007. (Pubitemid 47076658)
46. Rahman KW, Li Y, Wang Z, Sarkar SH and Sarkar FH: Gene expression profiling revealed survivin as a target of 3,3′-diindolyl-methane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 66: 4952-4960, 2006.